We studied hepatic iron overload (HIOL) 
A b s t r a c t

We studied hepatic iron overload (HIOL) patterns in 32 patients who underwent liver biopsies and testing for HFE mutations (C282Y, H63D). Iron-stained biopsy specimens were examined for patterns of iron deposits: hereditary hemochromatosis (HH) pattern or non-HH pattern. Visual iron grade based on amount of cellular and lobular iron was evaluated. We found the HH pattern in 17 biopsy specimens (53%) and the non-HH pattern in 6 specimens (19%). HH with superimposed non-HH was noted in 9 cases (28%). In 25 patients with HFE mutations, HH alone and combined with non-HH patterns was noted in 22 specimens (88%). Visual iron grade correlated approximately with the hepatic iron index. Heavy HIOL was noted in C282Y homozygotes and 1 patient with cirrhosis without either HFE mutation. Mild steatohepatitis was found in 21 specimens (66%); it was associated with the non-HH pattern in 80%
and the HH pattern in 62% (16/26) 
of cases. Liver biopsy can identify pattern and grade of HIOL and associated pathology for diagnosis and management of patients with abnormal iron studies and elevated liver function test results. Genetic tests for HFE mutations and liver biopsies are complementary in the workup of these patients.
Pathologists interested in liver disease often are confronted with a dilemma when a liver biopsy specimen contains iron deposits. Does stainable iron in a liver biopsy specimen represent hereditary hemochromatosis (HH) or some other form of hepatic iron overload? This distinction is important for accurate diagnosis, prognosis, and management, since HH is a common and readily treatable disease when identified in the early asymptomatic stages. 1, 2 This disorder was recognized originally by Von Recklinghausen in 1889 and later identified as a single inborn error of iron metabolism by Joseph Sheldon in 1935. 1, 2 The pattern of hepatic iron deposits in patients with HH and their relatives was first described by Scheuer et al 3 in a classic article published in 1962. Iron stains performed on liver biopsy specimens from these individuals revealed iron granules in particulate form and occasionally as a diffuse blue tinge within hepatocytes. The granules were present near the biliary borders of hepatocytes with an iron concentration gradient from the periphery of the lobule to centrilobular areas. For the past 40 years, pathologists have used this pattern as a diagnostic criterion suggestive of HH. The value of this pattern was again confirmed by Deugnier et al 4 in their review of liver biopsy pathology in 135 patients homozygous for genetic hemochromatosis. In their study, iron distribution within the hepatic lobule showed a decreasing gradient from periportal areas to centrilobular areas in 93.4% of patients. 4 Liver biopsy specimens also have been used for the quantitative measurement of hepatic iron concentration. In 1986, Bassett et al 5 showed that a hepatic iron index (HII = hepatic iron concentration in micromoles per gram of dry weight divided by age) of 1.9 or more reliably separated patients homozygous for HH who require therapy from patients with nonprogressive iron overload.
The genetic aspects of HH were determined originally from pedigree studies in France that demonstrated a linkage of the disease with the HLA complex on chromosome 6. 1, 2, 6 The hemochromatosis gene (HFE) was identified by Mercator Genetics in 1996, and it was quickly established that most cases of HH were associated with a single major missense mutation (G to A at nucleotide 845) resulting in a substitution of tyrosine for cysteine at amino acid 282 (C282Y). A second mutation (C to G at nucleotide 187) with a substitution of aspartate for histidine at amino acid 63 (H63D) was shown to be associated with iron overload in a minority of cases. 6 The role of liver biopsy for the diagnosis of HH in the era of genetic testing is being questioned. 6 Only 1 study has been published on the histologic evaluation of iron in liver biopsy specimens from patients with HFE mutations. 7 Our aim was to provide additional information on liver biopsy pathology and patterns of iron overload in a series of patients tested for HFE mutations. We also correlated pathologic features with clinical data to show that liver biopsy continues to have a significant role in the diagnosis and management of patients with elevated results of iron studies and abnormal liver function test (LFT) results, even in the era of genetic testing.
Materials and Methods
We included specimens from 32 patients who had liver biopsies and tests for HFE mutations in this retrospective study. Quantitative iron measurements were available for 23 cases. Iron stains (Prussian blue method) of all biopsy specimens were reviewed independently by 2 observers (S.N., G.N.) without knowledge of clinical data. Hepatic iron deposits were examined for the pattern within the lobule and distribution within cell types and also quantified for an approximate visual iron grade (trace, 1+, 2+, 3+) using a modification of the original method described by Scheuer et al. 3 In their original publication, these authors studied iron deposits in liver biopsy sections stained by the Prussian blue method with grade 0 being negative and grades 1, 2, 3, and 4 representing increasing amounts of stainable iron. Deposits were heaviest in the periphery of the lobule with a concentration gradient toward the center of the lobule. Our modification included "trace deposits" as heterogeneous iron deposits in periportal hepatocytes; grade 1, iron deposits homogeneous in periportal hepatocytes; grade 2, iron deposits filling hepatocytes up to the midlobule; and grade 3, iron deposits filling the entire lobule or blue cirrhotic nodules. Intermediate grades (trace to 1+, or 2+ to 3+) were used if there was variability of iron deposits within the section.
Iron deposits in reticuloendothelial cells were specified and similarly graded. Hepatocellular iron deposits with a decreasing gradient from periportal to centrilobular areas in the liver recently have been referred to as the HH pattern. 7 Iron deposits primarily in reticuloendothelial cells and macrophages with occasional heterogeneous deposits in periportal hepatocytes are referred to as the non-HH pattern. 7 If iron deposits were present in hepatocytes with a portal to central lobular gradient and iron also was noted in macrophages and sinusoidal lining cells, we considered the pattern to be a combined HH with superimposed non-HH pattern. Since most liver biopsy specimens were submitted by hepatologists to "rule out hemochromatosis," H&E and trichrome stains were reviewed to identify other pathology. Chronic hepatitis was graded and staged according to Batts and Ludwig 8 and steatohepatitis as grades 1, 2, or 3 according to a modification of a method described by Brunt et al. 9 These authors graded steatohepatitis as mild (grade 1), moderate (grade 2), or severe (grade 3) based on the amount and location of steatosis, ballooned hepatocytes, and intraacinar and/or portal inflammation with mononuclear cells and/or neutrophils. Our modification allowed mononuclear inflammation alone in grade 1 and included intracytoplasmic Mallory hyaline in grade 3.
The hepatic iron index (HII = quantitative iron in micromoles/gram divided by patient age) was calculated in cases in which quantitative iron measurements were available. All studies of quantitative iron measurements were performed by Mayo Medical Laboratories, Rochester, MN.
Genetic studies for both major and minor mutations were performed at reference laboratories (SmithKline Beecham Clinical Laboratories, Cambridge, MA; Kimball Genetics, Denver, CO; Baylor DNA Diagnostic Laboratory, Houston, TX; Mayo Medical Laboratories; Quest Diagnostics, Cambridge, MA) when requested as part of the clinical workup of the patient. In some patients previously diagnosed as having HH based on well-established clinical criteria, genetic studies were performed in the hospital laboratory on blood removed at the time of phlebotomy using a standard method. 10 Clinical data were obtained from liver biopsy requisitions as given by hepatologists. These data were as follows: (1) abnormal or elevated results of iron studies, occasionally specifically as elevated serum ferritin; (2) abnormal liver function test (LFT) results; or (3) "rule out hemochromatosis." Clinical and pathologic correlations were tabulated for all cases.
Cases were grouped according to the results of tests for HFE mutations as homozygous or heterozygous for the C282Y or H63D mutations or as compound heterozygotes for C282Y/H63D resulting in 5 groups. Group 6 comprised all cases in which neither mutation was identified ❚Table 1❚.
Results
Group 1: C282Y/C282Y
Four women (42-65 years old) and 8 men (40-60 years old) were identified in this group (Table 1) . The men were a mean age approximately 8 years younger than the women (47.4 vs 55.2 years), and twice as many men were identified in this group. All 12 patients had abnormal results of iron studies, and only 1 patient had a specific family history of HH. One woman and 2 men were reported to have elevated LFT results in addition to abnormal results of iron studies. Eight patients had the characteristic HH pattern of iron deposits in liver biopsy specimens ❚Image 1A❚. Four patients showed an HH pattern with a superimposed non-HH pattern ❚Image 1B❚. There were no biopsy specimens in this group with the non-HH pattern alone. The amount of iron in each biopsy specimen as identified by our simple visual grading system seemed to correlate approximately with quantitative iron studies as given by the HII, with 1+ associated with an HII of less than 1.9, 2+ with an HII of more than 2, and the highest grade, 3+ (iron deposits filling all hepatocytes in most or all lobules in the biopsy), correlating with an HII of 4.4 and 8.3 in a 40-year-old man and a 52-year-old woman, respectively. Steatohepatitis was an additional finding in 7 patients (58%). In all patients, this was predominantly macrovesicular steatosis in approximately half of the lobule or less, with rare ballooned hepatocytes and minimal foci of mononuclear inflammation and occasional neutrophils ❚Image 2A❚. Steatohepatitis was identified in 4 biopsy specimens with only the HH pattern of iron overload. In 3 other biopsy specimens, steatohepatitis was associated with the HH pattern with a superimposed non-HH pattern ❚Image 2B❚.
Genetic tests were performed after liver biopsies in all cases.
Group 2: C282Y/H63D
Three men (25, 50, and 53 years old) had elevated results of iron studies and elevated LFT results (Table 1) .
Two patients demonstrated iron overload in liver biopsy specimens with an HH pattern, and 1 patient had an HH pattern with a superimposed non-HH pattern. Quantitative iron measurements were available for only 1 patient with trace to 1+ hepatocellular iron deposits correlating with an HII of 1.6. Two patients had steatohepatitis, grade 1, which was associated with the HH pattern in one biopsy specimen and with HH with superimposed non-HH in the other specimen.
Genetic tests were performed after liver biopsy in all 3 patients. 
Group 3: H63D/H63D
One woman (74 years old) with elevated results of iron studies and a family history of HH and 1 man (62 years old) with elevated ferritin levels were included in this group (Table 1) . In the woman, hepatocellular iron deposits with an HH pattern graded as 1+ to 2+ ❚Image 3❚ corresponded to an HII of 1.3. In the man, hepatocellular iron deposits showed an HH pattern (1+) with a superimposed non-HH pattern (trace) and a corresponding HII of 1.1. The biopsy specimen from the man also showed steatohepatitis, grade 1.
Genetic tests were performed before liver biopsy in both patients.
Group 4: C282Y/-
One woman (60 years old) and 5 men (mean age, 46.4 years) were included in this group (Table 1) . Iron deposits with an HH pattern were identified in 3 biopsy specimens, and an HH pattern with a superimposed non-HH pattern was found in 1 biopsy specimen. Two biopsy specimens showed only the non-HH pattern of minimal iron deposits in sinusoidal cells and focal bluish stain in hepatocytes ❚Image 4❚. Quantitative iron levels were available for only 3 patients, and for all 3, an HII of less than 1 correlated with trace to 1+ deposits. All biopsy specimens showed other pathology, either steatohepatitis (4 cases) or chronic hepatitis (2 cases). One patient with chronic hepatitis C had iron deposits with an HH pattern, trace to 1+ ❚Image 5A❚. Steatohepatitis was identified in 2 biopsy specimens with the HH pattern, in 1 biopsy specimen with the non-HH pattern, and with the combined HH and non-HH pattern in 1 case.
Four patients with elevated results of iron studies or elevated serum ferritin levels had the genetic test performed before the liver biopsy.
Group 5: H63D/-
Two women (40 and 58 years old) were included in this group; for both, liver biopsies were done with cholecystectomy ( Table 1 ). The 40-year-old had iron overload with an HH pattern (grade 1+ correlating with an HII of 1.3) ❚Image 5B❚, as well as changes consistent with early large duct obstruction. The other patient had trace iron overload with a non-HH pattern and steatohepatitis, grade 1.
Genetic tests were performed after liver biopsy in both patients. 
A B ❚Image 4❚ (Case 19) A and B, Hepatic iron overload, non-hereditary hemochromatosis pattern, 1+ (iron stain, ×500). © American Society for Clinical Pathology
Group 6: -/-Three women (mean age, 59.7 years) and 4 men (mean age, 51.8 years) were included in this group (Table 1) . Iron deposits with the HH pattern were identified in 2 biopsy specimens. The non-HH pattern alone was noted in 3 specimens. Two biopsy specimens showed an HH pattern with a superimposed non-HH pattern, one of which was a cirrhotic liver with iron deposits in hepatocytes, reticuloendothelial cells, macrophages, bile ducts, and vessels ❚Image 6❚. The HII when available was less than 1.0, corresponding to a visual grade of trace to 1+, except in the cirrhotic liver in which a visual grade of 3+ corresponded with an HII of 7.1. Steatohepatitis was present in 6 biopsy specimens: in 2 specimens with the HH pattern, 3 specimens with the non-HH pattern, and 1 specimen with the combined pattern.
Genetic tests were performed after biopsy in the 3 women and before biopsy in the 4 men, all of whom had elevated results of iron studies. No known HFE mutations were identified in these 7 patients.
Summary of Liver Biopsy Data
Three patterns of iron overload were identified in these 32 biopsy specimens: HH alone in 17 specimens (53%), non-HH alone in 6 specimens (19%), and HH with a superimposed non-HH pattern in 9 specimens (28%). In patients with identified HFE mutations, the HH pattern or HH pattern with non-HH pattern was noted in 22 (88%) of 25 biopsy specimens.
Our semiquantitative visual iron grading showed an approximate correlation with the HII. Heavy iron overload corresponding to a visual grade of 2+ to 3+ was noted in C282Y homozygotes, and 10 of 12 patients in this group had an HII of more than 2.0. The highest HII (8.3) was identified in 1 woman in this group with hepatocellular iron graded as 3+ and iron in the portal macrophages and sinusoidal cells graded as 2+. A similar visual iron grade with an HII of 7.3 was present in the patient with cirrhosis without an HFE mutation. Iron overload was mild (1+ to 2+) in all other biopsy specimens correlating with an HII of less than 1.9 (when the HII was available). ❚Image 6❚ (Case 27) Cirrhosis with hepatic iron overload, hereditary hemochromatosis (HH) pattern, 3+, and non-HH pattern, 2+ (iron stain, ×100).
Steatohepatitis was identified in 21 (66%) of 32 biopsy specimens. When correlated with the patterns of iron overload, steatohepatitis was identified in 9 (53%) of 17 specimens with the HH pattern, 5 (83%) of 6 with the non-HH pattern, and 7 (78%) of 9 with the combined HH and non-HH pattern. Steatohepatitis was noted in 12 (80%) of 15 biopsy specimens with a non-HH pattern alone or combined and in 16 (62%) of 26 specimens with the HH pattern alone or combined. However, a statistically significant difference associating steatohepatitis with the non-HH pattern of iron overload could not be proven using the Fisher exact test (P > .05).
Summary of Genetic Test Results
In this study, 22 patients underwent testing for HFE mutations performed after liver biopsies. The genetic tests identified 2 C282Y homozygotes in group 1 who had an HII of less than 1.9 and 1 compound heterozygote for whom an HII was not available. The presence of these HFE mutations confirmed the diagnosis of genotypic HH in these 3 patients. In the other patients, identification of an HFE mutation was complementary to the diagnostic information obtained from liver biopsies.
Ten patients had HFE mutations identified before liver biopsy in order to explain the elevated results of iron studies. The HFE mutations identified included 2 H63D homozygotes, 4 C282Y heterozygotes, and 4 patients without a known HFE mutation. Follow-up liver biopsies were necessary to identify the presence, pattern, and amount of hepatic iron overload. The liver biopsies also revealed steatohepatitis in 9 of 10 patients and helped to guide further management.
Discussion
The HH pattern of iron deposits as originally described by Scheuer et al 3 was identified in 17 (53%) of 32 biopsy specimens in all groups in our study. Of these, 8 (47%) were from patients homozygous for the C282Y mutation. This finding seems to be similar to the results of a recent study in which 58% of patients with HH pattern on biopsy were homozygous for C282Y. 7 The second most common mutation reportedly associated with phenotypic HH is C282Y/H63D. There were 3 patients in this group in our study, and 2 showed the HH pattern. This pattern also was noted in one H63D homozygote, 1 H63D heterozygote, 3 C282Y heterozygotes, and 2 patients without either mutation. The non-HH pattern was noted only in 6 (19%) of 32 biopsy specimens, and this pattern seems to be an uncommon pattern of iron overload in patients with HFE mutations as previously suggested. 7, 11 Patients with the non-HH pattern included 2 C282Y heterozygotes and 1 H63D heterozygote, as well as 3 patients without an identified HFE mutation. Our study confirms earlier observations that hepatic iron overload with the non-HH pattern alone is not seen in C282Y homozygotes and compound heterozygotes. 7 The third pattern of hepatic iron overload, HH with a superimposed non-HH pattern has not been described previously and was identified in 9 (28%) of 32 biopsy specimens. These 9 specimens included 4 C282Y homozygotes and 1 compound heterozygote. In our series, the HH pattern alone or combined with a non-HH pattern was present in 22 (88%) of 25 biopsy specimens from patients with identified HFE mutations and, thus, seems to be the dominant pattern of hepatic iron overload in these patients.
Although clinical studies reporting the frequency of HFE mutations in patients with phenotypic HH show that homozygosity for C282Y is present in 60% to 100% of patients and that compound heterozygotes (C282Y/H63D) represent 3% to 5% of patients with phenotypic HH, 6 the role of C282Y and H63D heterozygosity in iron overload is not known. Both of these mutations have been identified in control subjects more often than in patients with HH. 12, 13 In population studies from northern Europe, C282Y heterozygosity was identified in 10% to 20% of persons studied, but only in 2% of patients with iron overload. 6 It is likely that in this group of patients, other environmental and/or genetic factors may have a role in increased iron absorption with subsequent iron overload. 12, 13 The role of H63D in iron overload has been controversial. However a recent study has shown that when chromosomes with C282Y are excluded, H63D seems to have a significant association with iron overload in both the homozygous and heterozygous states. 10 In our study, only 4 (15%) of 26 biopsy specimens with the HH pattern were from patients without an identified HFE mutation. These findings are in keeping with reports that 0% to 21% of patients with phenotypic HH do not have the known HFE mutations. 1, 2, 6 New studies also show that there are other forms of hereditary iron overload that are unrelated to HFE mutations (non-HFE-associated hemochromatosis). 12, 13 Our study suggests that the HH pattern of iron deposits in a liver biopsy specimen will be associated with an HFE mutation in the majority of cases. The pathologist can correlate iron deposits with an HH pattern in the biopsy specimen with an HFE mutation when available or recommend genetic testing after biopsy, to identify the genotype of the patient and assist in family counseling. In a few cases in which the liver biopsy reveals mild iron overload with an HH pattern, the identification of C282Y homozygosity or compound heterozygosity will confirm the diagnosis of genotypic HH.
Steatohepatitis was an important additional finding in two thirds of the cases in this study. It was identified in 9 (53%) of 17 biopsy specimens with the HH pattern, 5 (83%) of 6 with the non-HH pattern, and 7 (78%) of 9 with the combined pattern of iron overload. A relationship between steatohepatitis and hepatic iron overload has been reported but is controversial. 14 In an Australian study of increased hepatic iron concentration in nonalcoholic steatohepatitis, 31% of patients were either homozygous or heterozygous for C282Y, and the authors suggested that these mutations were responsible for the mild iron overload in these patients. 15 However, the pattern of iron overload in liver biopsy specimens from these patients was not described. Steatohepatitis now is generally considered to be the hepatic component of the insulin resistance syndrome. The pattern of insulin resistance-associated hepatic iron overload was reported recently and seems to be quite different from the HH pattern. 11 Insulin resistance-associated hepatic iron overload is mild iron overload with a mixed mesenchymal-parenchymal distribution of iron deposits, greater in mesenchymal cells and heterogeneous in periportal hepatocytes. This is a nonspecific pattern and seems to be similar to the non-HH pattern. The periportal distribution of iron deposits with a gradient within the hepatic lobule characteristic of HH is due to increased absorption of intestinal iron through the portal vein, whereas iron deposits in sinusoidal lining cells, portal macrophages, and occasionally in hepatocytes (non-HH pattern) most likely are related to the inflammation, necrosis, and steatosis associated with steatohepatitis. 11 In our study, steatohepatitis seemed to be associated with the non-HH pattern as previously described 11 ; however, our numbers are too small to reach statistical significance. Pathologists must recognize all 3 patterns of hepatic iron overload, particularly the combined HH with non-HH pattern. When present in a liver biopsy specimen, this pattern supports a diagnosis of steatohepatitis in a patient with HH.
In the present study, we also demonstrated a rough correlation between visual iron grade in the biopsy specimen and HII in all groups. Marked iron overload, visual grade and by HII, was noted in C282Y homozygotes; however, 2 of 12 patients in this group had an HII of less than 1.9. Patients in all other groups had mild iron overload with an HII of less than 1.9, except for 1 patient with cirrhosis who did not have either known HFE mutation. Before the availability of genetic tests, a patient was considered "homozygous" for HH if the HII estimated from the liver biopsy specimen was more than 1.9. 5 A large multicenter study published a few years ago reported that the HII was more than 1.9 in 93% of patients with HH but less than 1.9 in 7%. 16 Reports also show that patients with cirrhosis may have an HII of more than 1.9 because cirrhotic livers seem to accumulate hepatic iron for multiple reasons, even in the absence of HH. 17, 18 In patients with HH and cirrhosis, a proposed new diagnostic cutoff level for HII is 4.2. 19 With the availability of genetic tests, the role of HII in establishing the diagnosis of HH is diminished. A patient should not be classified as homozygous or heterozygous based only on an HII value of more than 1.9. However, the HII does help to determine the degree of iron overload and guide appropriate patient management. 16 Iron deposits with a non-HH pattern usually are minimal to mild when associated with steatosis or steatohepatitis. Moderate to heavy mesenchymal deposits are noted primarily in biopsy specimens from patients with HH with heavy iron overload when excess iron in hepatocytes spills over into mesenchymal cells to produce a combined HH with non-HH pattern.
Liver biopsy continues to have an important role in the diagnosis, prognosis, and management of patients with elevated results of iron studies and abnormal liver function test results in general hepatology practice. We suggest that all such patients undergo genetic testing for the C282Y and H63D mutations, especially if there is a family history of hemochromatosis. This test is readily done on blood samples and is relatively inexpensive. It will establish the genotype of the patient and permit genetic counseling of family members. A liver biopsy may not be necessary in young C282Y homozygotes or compound heterozygotes without evidence of liver disease, and these patients can be followed up with iron studies and liver function tests every 2 years. 2 If HFE mutations other than C282Y homozygosity or compound heterozygosity are identified or if no HFE mutations are detected, the genetic information cannot explain abnormal results of iron studies. Liver biopsy should be considered to detect the presence and pattern of iron overload. The amount of iron present can be estimated and confirmed by quantitative iron studies. Patients with an elevated HII can be treated for iron overload by phlebotomy. C282Y homozygotes and compound heterozygotes who are older or demonstrate evidence of liver disease can benefit from undergoing liver biopsy, which will identify fibrosis, cirrhosis, or carcinoma. 13 Although noninvasive techniques to identify iron overload and fibrosis have been recommended, they are less reliable. 20 Finally, liver biopsy can document the presence of concomitant liver diseases, particularly steatohepatitis, to explain biochemical abnormalities and guide therapy. We believe that identification of HFE mutations and liver biopsies with quantitative iron studies are complementary for diagnosis and management of patients with elevated results of iron studies and abnormal liver function test results. 
